As of February 20, 2021, FDA has urgently authorized 14 COVID-19 antigen tests, involving 11 companies: Abbott、Ortho、Quidel 、BD、LumiraDx、Access Bio、Princeton BioMeditech、Luminostics、Celltrion、Quanterix、Ellume.

On the evening of February 19, FTSE Russell, an international index compilation company, announced the quarterly review results of its flagship index, adding 129 A-share targets in total. Edan Instruments (300206. SZ) officially entered the FTSE Russell.

Recently, a number of Chinese listed IVD companies released 2020 annual performance report, disclosing their revenue. Driven by the demand of testing products of COVID-19, the performance growth is very gratifying.

"Understanding which genes protect people from diabetes and cardiovascular disease will ultimately lead to better diagnosis and treatment of obese patients," the researchers said.

Today is March 4th, the International HPV Awareness Day. Let us learn about HPV together.

At present, six new COVID-19 antigen (home-use) kits have been authorized for emergency use by BfArM. The certification means that the product can be sold in German supermarkets, and local residents can use the product for self-testing.

Recently, Roche Diagnostics and Yunkang Group officially announced that they had reached further strategic cooperation.

During hot summer, water loss is larger, fitness enthusiast should pay attention to "moderate" exercise.

Recently, COVID-19 (SARS-CoV-2) Antigen Test Kit independently developed by Wuhan Easy Diagnosis passed the performance verification of Paul-Ehrlich-Institut in Germany.

Recently, the strategic business matchmaking meeting between Jointown medical devices group co., ltd. and Mindray was held in Shenzhen.

A total of 64.98 million people have been vaccinated with COVID-19 vaccine, according to the National Health Commission.

Roche announced on the 15th that it will acquire GenMark Diagnostics, a US molecular pathology laboratory manufacturer, for US$1.8 billion.

On March 17th, Jiangsu Bioperfectus Technologies Co., Ltd. signed a strategic cooperation agreement with HUIXIN LABORATORY.

SINOPHARM GROUP achieved business revenue of about 456.4 billion yuan, an increase of 7.32% year-on-year.

Amid the global scramble for vaccines, one positive piece of news is hard to ignore: vaccines do seem to work.